Asante Capital congratulates partner Abingworth on the final closing of its new Clinical Co-Development Co-Investment Fund at $356 million
We are delighted to share that Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today announced the final closing of its new Clinical Co-Development Co-Investment Fund at $356 million.